Non-IPF ILD exhibited three FVCpp trajectory clusters with annual absolute changes of –0.84%, +2.10%, and –6.30%, corresponding to 5-year terminal-outcome–free proportions of 82.0%, 73.1%, and 64.5%.
Trevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough. Click here to read why TRVI stock ...
Detailed price information for Trevi Therapeutics Inc (TRVI-Q) from The Globe and Mail including charting and trades.
Hosted on MSN
Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA alignment achieved
Trevi plans to initiate two Phase III trials in IPF-related chronic cough, with the first trial starting in Q2 2026 and the second in the second half of 2026, and expects to provide top line data from ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...
SAN FRANCISCO — The investigational oral agent nerandomilast was superior to placebo at slowing the decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis (PF), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results